LUMiC® Endoprosthetic Reconstruction After Periacetabular Tumor Resection: Short-term Results

Background: Advances in limb-salvage techniques have made total calcanectomy and primary reconstruction possible in managing calcaneal aggressive benign tumors and selected cases of intraosseous malignant tumors. However, there is still no consensus on the operative approach, oncologic margin, and the best reconstruction method to date. These 2 cases describe our experience in calcaneal reconstruction with the free deep circumflex iliac artery (DCIA) osseocutaneous flap in benign aggressive calcaneal tumors. Methods: We reported 2 consecutive male and female patients, with an average age of 25 years (age 19 and 31, respectively), who underwent total calcanectomy and primary calcaneal reconstruction with the free DCIA osseocutaneous flaps for calcaneal chondroblastoma and giant cell tumor. A marginal resection of the entire calcaneus through the subtalar and calcaneocuboid joints (intra-articular approach) was performed in the first case and a wide local resection leaving 1 cm normal calcaneal bone margin anterosuperiorly (intraosseous approach) was performed in the second case. Results: The follow-up period averaged 48 months. Negative oncologic margins were achieved in both cases. The first case was complicated with venous thrombosis; however, the graft remained viable after emergency reexploration. Normal foot function was restored with good solid osseous union and bony hypertrophy observed. Both patients achieved good short-term functional and aesthetic outcomes with no donor site pain or disability. No local recurrence was reported either. Conclusion: Primary calcaneal reconstruction with the free DCIA osseocutaneous flap can lead to good short-term functional and aesthetic outcomes. Level of Evidence: Level IV, case series.

Download Full-text

The short-term outcomes of primary tumor resection with synchronous metastases from pancreas neuroendocrine tumors: an analysis of the ACS-NSQIP registry

HPB ◽

10.1016/j.hpb.2019.03.176 ◽

2019 ◽

Vol 21 ◽

pp. S101-S102

Author(s):

N. Latchana ◽

L. Davis ◽

C.H.L. Law ◽

J.R. Howe ◽

R. Pommier ◽

...

Keyword(s):

Neuroendocrine Tumors ◽

Primary Tumor ◽

Tumor Resection ◽

Primary Tumor Resection ◽

Short Term ◽

Acs Nsqip ◽

Synchronous Metastases

Download Full-text

The evolution of pelvic endoprosthetic reconstruction after tumor resection

Annals of Joint ◽

10.21037/aoj.2019.06.01 ◽

2019 ◽

Vol 4 ◽

pp. 29-29

Author(s):

Tao Ji ◽

Wei Guo

Keyword(s):

Tumor Resection ◽

Endoprosthetic Reconstruction

Download Full-text

Short-term preoperative treatment of macroprolactinomas by dopamine agonists

Journal of Neurosurgery ◽

10.3171/jns.1987.67.6.0807 ◽

1987 ◽

Vol 67 (6) ◽

pp. 807-815 ◽

Cited By ~ 39

Author(s):

Rudolf Fahlbusch ◽

Michael Buchfelder ◽

Uwe Schrell

Keyword(s):

Dopamine Agonists ◽

Low Dose ◽

Tumor Resection ◽

Residual Tumor ◽

Cystic Tumor ◽

Preoperative Treatment ◽

Short Term ◽

Content Type ◽

Transsphenoidal Microsurgery ◽

Injectable Form

✓ During a period of 3 years, 25 patients with intra- and extrasellar macroprolactinomas were pretreated with dopamine agonists for a period of 2 to 6½ weeks prior to transsphenoidal microsurgical tumor resection. Dopamine agonists were administered orally to 17 patients, intramuscularly to three patients, and both orally and intramuscularly to five patients. Repeated computerized tomography (CT) examinations revealed that all neoplasms except one cystic tumor were reduced in size during the course of dopamine-agonist administration. No complications attributable to medical pretreatment were observed. Tumor shrinkage increased the efficacy of surgery, especially in cases with considerable extrasellar extension of the adenomas. Within 3 months following adenomectomy, prolactin levels were adjusted to normal levels in 19 patients by additional low-dose treatment with dopamine agonists. Thin-collimation CT assessments performed at least 3 months after surgery showed no evidence of residual tumor tissue in 23 patients. It is concluded that administration of dopamine agonists for some weeks prior to surgery is a useful adjunct to transsphenoidal microsurgery for macroprolactinomas. The new injectable form of bromocriptine is particularly valuable for this purpose.

Download Full-text

Internal Hemipelvectomy for Musculoskeletal Tumors—Indications and Options for Reconstruction

Oncology & Hematology Review (US) ◽

10.17925/ohr.2011.07.2.123 ◽

2011 ◽

Vol 07 (02) ◽

pp. 123

Author(s):

Adam J Schwartz ◽

Jeffrey J Eckardt ◽

Christopher P Beauchamp ◽

◽

...

Keyword(s):

Tumor Resection ◽

Functional Method ◽

Endoprosthetic Reconstruction ◽

Primary Tumors ◽

Internal Hemipelvectomy ◽

Musculoskeletal Tumors ◽

Risks And Benefits ◽

Bony Pelvis ◽

Metastatic Lesions ◽

Reconstruction Methods

Resection of all or part of the bony pelvis is commonly referred to as internal hemipelvectomy. This procedure is a common treatment for various localized primary tumors of the hemipelvis, and rarely for metastatic lesions. Options for reconstruction following tumor resection include allograft, allograft-prosthetic composite (APC), and endoprosthetic reconstruction. An alternative method of limb salvage following resection of the hemipelvis is resection arthroplasty. Controversy exists among musculoskeletal oncologists regarding the most durable and functional method of reconstruction. As primary musculoskeletal tumors involving the pelvis are rare, there are few well-designed studies from which to draw definitive conclusions. The purpose of this paper is to review the indications for internal hemipelvectomy and to examine the risks and benefits of the available reconstruction methods.

Download Full-text

Role of Race in Short-Term Outcomes for 1700 Consecutive Patients Undergoing Brain Tumor Resection

Journal for Healthcare Quality ◽

10.1097/jhq.0000000000000267 ◽

2020 ◽

Vol Publish Ahead of Print ◽

Author(s):

Debanjan Haldar ◽

Gregory Glauser ◽

James M. Schuster ◽

Eric Winter ◽

Stephen Goodrich ◽

...

Keyword(s):

Brain Tumor ◽

Tumor Resection ◽

Short Term ◽

Brain Tumor Resection

Download Full-text

Modular Endoprostheses for Nonneoplastic Conditions: Midterm Complications and Survival

BioMed Research International ◽

10.1155/2016/2606521 ◽

2016 ◽

Vol 2016 ◽

pp. 1-5 ◽

Cited By ~ 4

Author(s):

Marco De Gori ◽

Guido Scoccianti ◽

Filippo Frenos ◽

Leonardo Bettini ◽

Filippo Familiari ◽

...

Keyword(s):

Survival Rate ◽

Bone Loss ◽

Tumor Resection ◽

Viable Option ◽

Endoprosthetic Reconstruction ◽

Index Procedure ◽

Free Survival ◽

Severe Bone Loss ◽

Significant Difference

The use of modular endoprostheses is a viable option to manage both tumor resection and severe bone loss due to nonneoplastic conditions such as fracture sequelae, failed osteoarticular grafts, arthroplasty revisions, and periprosthetic fractures. We sought to investigate both midterm complications and failures occurred in 87 patients who underwent a megaprosthetic reconstruction in a nonneoplastic setting. After a mean follow-up of 58 (1–167) months, overall failure-free survival was 91.5% at 1 year, 80% at 2 years, 71.6% at 5 years, and 69.1% at 5 and 10 years. There was no significant difference in the survival rate according to the diagnosis at the index procedure (p=0.921), nor to the reconstruction site (p=0.402). The use of megaprostheses in a postneoplastic setting did not affect survival rate in comparison with endoprosthetic reconstruction of pure nonneoplastic conditions (p=0.851). Perimegaprosthetic infection was the leading complication, occurring in 10 (11.5%) patients and implying a megaprosthetic revision in all but one case. Physicians should consider these results when discussing with patients desired outcomes of endoprosthetic reconstructions of a nonneoplastic disease.

Download Full-text